Rancho Santa Fe, CA, United States of America

Erkki I Ruoslahti

This inventor holds 135 USPTO granted patents and 18 published patent applications and 12 EPO patents, primarily in Targeted Drug Delivery (CPC class C07K7-06). Top assignees: La Jolla Cancer Research Foundation, Sanford-Burnham Medical Research Institute, The Burnham Institute. Active years: 1983-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Erkki I Ruoslahti. Retrieved from https://idiyas.com/inventor/erkki-i-ruoslahti

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 135 (Patent Applications = 18)

% Patents Active = 75.6

EPO Patents = 12 (Patent Applications = 14)

Average Co-Inventor Count = 2.3

ph-index = 26

Forward Citations = 2,586(Granted Patents)

Forward Citations (Not Self Cited) = 2,314(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Rancho Sante Fe, CA (US) (1992 - 1999)
Olivenhain, CA (US) (1983 - 2001)
Ranco Santa Fe, CA (US) (2007)
San Diego, CA (US) (1997 - 2011)
San Francisdo, CA (US) (2013)
Bueuton, CA (US) (2013)
Busilton, CA (US) (2015)
Buelton, CA (US) (2016)
Buellton, CA (US) (2009 - 2022)
Rancho Santa Fe, CA (US) (1991 - 2024)
La Jolla, CA (US) (2010 - 2024)

Company Filing History:

54 out of 151

La Jolla Cancer Research Foundation

patents

27 out of 99

Sanford-Burnham Medical Research Institute

patents

26 out of 94

The Burnham Institute

patents

4. 13 out of 99

Sanford Burnham Prebys Medical Discovery Institute

patents

5. 10 out of 55

Burnham Institute for Medical Research

patents

6. 7 out of 16,035

University of California

Lisata Therapeutics, Inc.

patents

9. 1 out of 368

Kyungpook National University Industry-Academic Cooperation Foundation

patents

10. 2 out of 834,570

Other

patents

where one patent can have more than one assignee

Years Active: 1983-2026

Loading Chart...

Areas of Expertise:

Targeted Delivery

Tumor Targeting

Peptide Compositions

Cyclic Peptides

Macrophage Binding

Nervous System Injuries

Atherosclerotic Plaques

Alzheimer's Diagnosis

Vascular Regulation

Cancer Treatment

Clot Binding Compounds

Regenerating Tissue

135 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12751991 - Methods for treating pancreatic cancer and other solid tumors (2026-10-06),

2. 12708673 - METHODS AND COMPOSITIONS RELATED TO PEPTIDES AND PROTEINS WITH C-TERMINAL ELEMENTS (2026-08-18),

3. 12351653 - Pharmaceutical compositions comprising novel cyclic peptides (2025-07-08),

4. 12290569 - Methods and compositions using peptides and proteins with c-terminal elements (2025-05-06),

5. 12195558 - Targeted delivery system and methods of use therefor (2025-01-14),

6. 12023389 - Compositions that target tumor-associated macrophages and methods of use therefor (2024-07-02),

7. 11981752 - Tumor associated monocyte/macrophage binding peptide and methods of use thereof (2024-05-14),

8. 11642391 - Compositions containing a pharmacophore with selectivity to diseased tissue and methods of making same (2023-05-09),

9. 11571485 - Peptides and antibodies for detecting changes in alzheimer's disease brain and methods of use thereof (2023-02-07),

10. 11571484 - Compositions that target tumor-associated macrophages and methods of use therefor (2023-02-07),

11. 11512110 - Targeted delivery system and methods of use therefor (2022-11-29),

12. 11458210 - Compounds and compositions for targeting brain injuries and methods of use thereof (2022-10-04),

13. 11376303 - Compositions and methods for treating nervous system injuries (2022-07-05),

14. 11260133 - Methods and compositions related to peptides and proteins with C-terminal elements (2022-03-01),

15. 11059718 - Methods and compositions using peptides and proteins with C-terminal elements (2021-07-13),

Title: The Innovative Mind of Erkki I Ruoslahti

Introduction: Erkki I Ruoslahti, a distinguished inventor based in Rancho Santa Fe, CA (US), is renowned for his groundbreaking contributions to the field of biotechnology and medical research.

Latest Patents: Erkki I Ruoslahti holds several patents in the areas of targeted drug delivery systems, cell adhesion molecules, and tumor microenvironment modulation, showcasing his continuous commitment to innovation.

Career Highlights: With a career spanning several decades, Erkki I Ruoslahti has made significant strides in the development of novel therapies for cancer treatment, particularly focusing on utilizing nanotechnology for precise drug delivery to tumor cells.

Collaborations: Throughout his career, Erkki I Ruoslahti has collaborated with leading research institutions, pharmaceutical companies, and biotechnology firms to further advance his pioneering research in the field of molecular medicine.

Conclusion: Erkki I Ruoslahti's relentless pursuit of innovation and his profound impact on the field of biotechnology and medical research solidify his position as a visionary inventor whose work continues to shape the future of healthcare.

Profile summary based on public USPTO records.